phrykt

Entera Bio Ltd. (ENTX): who owns it and who trades it

As of Nov 16, 2026, ENTX insiders reported 8 purchases worth $141K in the last 12 months. The largest buyer was Geno J Germano (Director), with $55.8K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Entera Bio

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ENTX

27 funds and institutions reported ENTX shares worth $19M at the end of Q2 2026, about 23% of the company. The largest holder is Knoll Capital Management, LLC with 12.6%.

Funds and institutions (13F) 23%Everyone else 77%

10 largest owners, by share of the company

Knoll Capital Management, LLC12.6%
Bvf Inc5.2%
Siren, L.L.C.1.6%
Renaissance Technologies LLC0.8%
Parkman Healthcare Partners LLC0.6%
PNC Financial Services Group, Inc.0.6%
Seven Fleet Capital Management LP0.4%
HighTower Advisors, LLC0.2%
Hrt Financial LP0.2%
Schonfeld Strategic Advisors LLC0.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Knoll Capital Management, LLC5.88M12.62%$10.4M–
Bvf Inc2.42M5.20%$4.3M–
Siren, L.L.C.736,4571.58%$1.3M–
Renaissance Technologies LLC368,8470.79%$653K–
Parkman Healthcare Partners LLC274,4970.59%$486K–
PNC Financial Services Group, Inc.273,0310.59%$483K–
Seven Fleet Capital Management LP191,3540.41%$339K–
HighTower Advisors, LLC74,5730.16%$133K–
Hrt Financial LP72,4860.16%$128K–
Schonfeld Strategic Advisors LLC58,8710.13%$104K–
Two Sigma Securities, LLC48,5930.10%$86K–
Signature Estate & Investment Advisors LLC47,3280.10%$83.8K–
JPMorgan Chase & Co40,8830.09%$67.5K–
Citadel Advisors LLC38,8040.08%$68.7K–
Virtu Financial LLC36,9210.08%$65K–
Geode Capital Management, LLC29,9080.06%$52.9K–
Diadema Partners LP23,2600.05%$41.2K–
XTX Topco Ltd20,5590.04%$36.4K–
Gem Investment Advisors, LLC19,1350.04%$33.9K–
Jane Street Group, LLC17,3310.04%$30.7K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ENTX insiders reported $141K of open-market purchases and $0 of sales.

Purchases, 12 months
$141K
8 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Mar 9, 2026
Filed Mar 11, 2026

Purchases and sales by month

$82.7K$82.7KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 9, 2026Geno J GermanoDirectorPurchase20,000$1.30$26KForm 4
Mar 5, 2026Sean EllisDirectorPurchase10,000$1.23$12.3KForm 4
Feb 12, 2026Steven D RubinDirectorPurchase5,000$1.49$7.5KForm 4
Feb 10, 2026Haya TaitelDirectorPurchase7,500$1.48$11.1KForm 4
Feb 10, 2026Geno J GermanoDirectorPurchase20,000$1.49$29.8KForm 4
Feb 9, 2026Steven D RubinDirectorPurchase10,000$1.20$12KForm 4
Feb 9, 2026Sean EllisDirectorPurchase18,000$1.24$22.3KForm 4
Dec 29, 2025Miranda Jayne ToledanoCEOPurchase11,000$1.81$19.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Geno J GermanoDirector$55.8K–Mar 9, 2026
Sean EllisDirector$34.6K–Mar 5, 2026
Miranda Jayne ToledanoChief Executive Officer, Director$19.9K–Dec 29, 2025
Steven D RubinDirector$19.4K–Feb 12, 2026
Haya TaitelDirector$11.1K–Feb 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ENTX short interest

Low short interest. 4.1% of ENTX shares are sold short: about 1 share in 24. Over the last 12 reports the number of shares short went up 3790%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.07M ENTX shares were sold short, 4.1% of the shares outstanding, up 27.4% from the report before. At the average daily volume of 453,441 shares, buying them all back would take about 15.6 trading days (days to cover).

Shares short, % of all shares

4.08%May 15Oct 304.64%

Days to cover

15.6May 15Oct 3017.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.07M4.08%+27%453,44115.6
Oct 15, 20265.55M3.20%+131%773,3737.2
Sep 30, 20262.40M1.39%+88%464,3195.2
Sep 15, 20261.28M0.74%+45%358,6523.6
Aug 31, 2026885,9450.51%-7%358,3742.5
Aug 14, 2026956,7580.55%-17%499,0231.9
Jul 31, 20261.15M2.47%+287%7.66M1.0
Jul 15, 2026297,4520.64%-11%225,2731.3
Jun 30, 2026332,6580.71%+108%5.61M1.0
Jun 15, 2026160,1180.34%-10%55,5032.9
May 29, 2026177,6700.38%-2%75,9212.3
May 15, 2026181,7680.39%-5%134,4341.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Entera Bio company events

Entera Bio filed 13 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Oct 27, 2026LeadershipThe Board of Directors of Entera Bio Ltd., a company organized under the laws of the State of Israel, appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director of the Company, effective December 1, 2026. Filing
  3. Oct 6, 2026LeadershipThe Board of Directors of Entera Bio Ltd., a company organized under the laws of the State of Israel, appointed Laura Hamill as a Class I director of the Company, effective December 1, 2026. Filing
  4. Aug 18, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01. Filing
  5. Aug 7, 2026ResultsReleased financial results. Filing
  6. Jul 28, 2026LeadershipThe information set forth under Item 1.01 of this Current Report on Form 8-K regarding the BVF Designees and the New Independent Directors is incorporated by reference into this Item 5.02. Filing
  7. Jul 16, 2026LeadershipAt the Annual Meeting (as defined in Item 5.07 to this Current Report on Form 8-K) of Entera Bio Ltd., a company formed under the laws of the State of Israel, the Company’s shareholders approved an amendment to the Company’s 2018 Equity Incentive Plan to increase the number of ordinary shares, par… Filing
  8. May 8, 2026ResultsReleased financial results. Filing
  9. Apr 3, 2026AgreementEntera Bio Ltd., a company organized under the laws of the State of Israel, entered into a Securities Purchase Agreement with funds affiliated with BVF Partners LP, providing for the private placement to the Purchaser of an aggregate of 7,827,789 units, each Unit consisting of (i) one ordinary… Filing
  10. Mar 27, 2026ResultsReleased financial results. Filing
  11. Mar 4, 2026AnnouncementShared information with investors. Filing
  12. Feb 9, 2026LeadershipAppointment of Geno J. Germano as a Director and Chairman of the Board The Board of Directors of Entera Bio Ltd., a company organized under the laws of the State of Israel appointed Geno J. Germano as a Class III director of the Company and as Chairman of the Board, effective February 4, 2026. Filing
  13. Feb 4, 2026LeadershipGerald Ostrov notified the Board of Directors of the Company of his resignation as a Director, effective February 1, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Entera Bio financials

Famous investors that hold ENTX

2 of the 50 well-known investors we track reported holding ENTX in their latest 13F filing. The largest position is Jim Simons's, worth $422K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026144,900$422K0.0%-61%
Ken Griffin · Citadel AdvisorsQ3 2026122,438$356K0.0%+216%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ENTX in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Spruce Street Capital LP13G6.4%
Nov 13, 2026Spruce Street Capital LP13G6.4%
Oct 30, 2026Venrock Healthcare Capital Partners III, L.P.13G5.1%
Oct 30, 2026Venrock Healthcare Capital Partners III, L.P.13G5.1%

Questions about Entera Bio Ltd. (ENTX) stock

Who owns the most ENTX stock?

The largest reported owner of Entera Bio Ltd. (ENTX) is Knoll Capital Management, LLC, with 12.6% of the company. In total, 27 funds and institutions reported holding ENTX at the end of Q2 2026, together about 23% of the shares. See the largest owners.

Are ENTX insiders buying or selling?

In the last 12 months, ENTX insiders reported 8 open-market purchases worth $141K and no sales. The latest trade was on Mar 9, 2026. See every trade.

What is the short interest in ENTX?

As of Oct 30, 2026, 7.07M ENTX shares were sold short, 4.1% of the shares outstanding, up 27.4% from the report before. At the average daily volume of 453,441 shares, buying them all back would take about 15.6 trading days (days to cover). See the history.

Which famous investors hold ENTX?

2 of the 50 well-known investors we track reported ENTX in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $422K. See all holders.

Executive pay

Entera Bio's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025, up 29% from $1.1M the year before. In the last 12 months, Entera Bio's executives and directors bought $141K of stock on the open market and sold none.

Chief executive, total pay$1.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$518KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.